

A Case of Varicella Zoster Infection in Kidney Transplant Recipient using immunosuppressant

Abdirahim Ali Nur Adam¹, Abdulrashid Hashi Mohamed¹, and Mohamed Osman Omar Jeele¹

¹Somalia Mogadishu Turkey Recep Tayyip Erdogan Training and Research Hospital

May 31, 2023

Introduction:

To prevent acute or chronic allograft rejection, recipients of kidney transplants are needed to take immunosuppressive for the rest of their lives. However, their compromised immune system put them at risk for opportunistic infections as well¹. Infection with the varicella-zoster virus (VZV) is an unusual in recipients of kidney transplants at a frequency rate from 1% to 11%, but the severity is more significant in transplant patients compared to the overall population^{2, 3}. Fever and a self-limiting rash on the skin and occasionally the mucosa may be the present symptoms of varicella infection. Additionally observed symptoms include headache, malaise, and appetite loss. The rash starts off as macules, quickly develops into papules and then goes through a vesicular stage and crusts over the lesions. After one to two weeks, crusts flake off⁴. Disseminated herpes zoster (HZ) in kidney transplant recipients can result in a very high overall mortality rate of up to 30%⁵.

Here we describe a 23-year-old male patient with a history renal transplant who presented to the emergency department with complaint of high grade fever, chills and generalized rash for 5 days.

Case presentation:

A 23-year-old male patient presented to the emergency department with a complaint of high grade fever, chills and generalized rash for 5 days. The patient was diagnosed with the end-stage renal disease 4 years ago which he was put on routine hemodialysis program for 1 year. He underwent renal transplant 3 years ago and since then he did not needed any hemodialysis sessions. Following his renal transplant surgery the patient was put under immunosuppressants drugs (mycophenolate mofetil, steroids and tacrolimus). He had no known history of chickenpox at young age, no history of diabetes. He never had any vaccination following his renal transplant including varicella vaccine. There was no history of contact with chickenpox patient.

On presentation, the patient was fully conscious, alert and co-operative and with the following vital signs: BP 145/90 mmHg, pulse 90 times per minute, RR 14 bpm, and temperature 38.6 °C. On examination, there was no jaundice or anemic conjunctiva. He had no palpable lymph nodes, discomfort, or stiffness in the neck. The rashes were variously healed widespread erythematous papules and vesicles in the face and trunk (Figure 1). Chest examination was within normal limit with no rales or wheezing. He had normal bowel sounds on abdominal examination with no organomegaly. Limb examination showed adequate turgor and no edema, inguinal lymph nodes were not palpable. Blood tests revealed a hemoglobin (Hb) level of 16.6 g/dl, hematocrit (Ht) 49.8%, leukocyte 7.60/mm³, platelet 200,000/mm³, MCV 87.9 fl, MCH 29.4pg, MCHC 33.4, creatinine 0,82mg/dl, urea 34 mg/dl random blood glucose (RBS) 110mg/dl, Sodium 142mEq/l, potassium 3,84mEq/l. Urine examination was unremarkable. Abdominal ultrasonography only revealed bilateral atrophic kidneys and transplanted kidney in the pelvic region.

The patient was admitted to infectious disease department under the diagnosis of chickenpox infection using clinical assessment. He was started with intravenous acyclovir 3x750mg for 5 days which was later switched to oral acyclovir 5*800mg and acyclovir lotion and antipyretics.

As his rash started subsiding with normal temperature he was discharged to home with close monitoring. After 3 weeks the patient came for follow-up his rashes had drastically improved and had no fever or chills (figure 2).

Discussion:

Kidney transplantation is a therapeutic choice for end-stage renal disease. Kidney transplantation offers the patients a better quality of life as they are free from fluid and potassium restriction, better metabolic function and normal hemoglobin as normal kidney function return⁶. Immunosuppressants are essential for the allograft function to be successful. These medications function by reducing the allograft rejection response and are used for maintenance, treating rejection reactions, and induction (strong immunosuppression in the early days after transplantation). However, using immunosuppressants also has drawbacks⁶. The body will be more vulnerable to a variety of opportunistic infections due to the body's immune system being suppressed, which can both jeopardize the outcome of kidney transplants and result in fatalities^{7, 8}. Up to 44.9–82% of recipients of kidney transplants get infections postoperatively, including viral infections like cytomegalovirus and varicella as well as urinary tract infections and pneumonia. The highest percentages of infections among patients who are on immunosuppressants are caused by bacteria, fungi, and viruses in 50%, 30%, and 5%, respectively; while 15% of infections are considered as polymicrobial⁹. Fever, pneumonia, enteritis, meningitis, and encephalitis are some of the clinical manifestations of viral infections. As a result, the immune system is suppressed, which raises the risk of opportunistic infections¹⁰.

For the past three years, our patient has been living with a transplanted kidney and during that time there have been no complaints. He was using corticosteroids, mycophenolate mofetil, and tacrolimus as his three immunosuppressants.

Rapid diagnosis is necessary to select the appropriate antiviral therapy in immunocompromised patients at the time of acute VZV infection. Tissue culture can be used to isolate VZV; this technique is not, however, quick enough to affect therapeutic decision-making. The virological assay to identify VZV antigens using monoclonal antibodies is the quickest test. Due to a lack of resources, neither culture isolation nor any other techniques were used to diagnose this patient. The clinical signs actually showed varicella infection (chickenpox)¹¹.

Giving an antiviral medication as soon as possible, preferably within the first 24 hours after the rash initially starts, will produce the best results. Antiviral medication can be substituted orally if clinical improvement occurs¹².

Although being the high risk group for infections, Vaccinations had never been administered to our patient before. Some recommendations call for the delivery of vaccines to every patient receiving an organ transplant. Seronegative individuals should receive two doses of pre-transplant immunization, spaced four weeks apart, to help prevent serious infection. The chosen vaccine must be suitable for chronic kidney disease patients¹³.

Conclusions:

Patients undergoing kidney transplants frequently have immunosuppressive conditions, making them more susceptible to infection. The varicella-zoster virus vaccine is required to protect the kidney transplant patient from infection. Antiviral medication should be taken into consideration if kidney transplant recipients have a serious varicella infection.

Abbreviations

VZV: Varicella-zoster virus

HZ: Herpes zoster

Ethics Committee approval and consent for publication:

Mogadishu-Somali Turkish Training and Research Hospital ethics committee waived approval for this case report. Written informed consent was obtained from the patient to publish the details and the images in this case report anonymously.

Acknowledgments

N/A

Funding

The authors declare no funding source for this research.

Disclosure

The authors declare no competing interests in relation to this study.

Reference

1. Fishman JA. Opportunistic infections—coming to the limits of immunosuppression?. *Cold Spring Harbor perspectives in medicine*. 2013 Oct 1;3(10):a015669.
2. Guess HA, Broughton DD, Melton III LJ, Kurland LT. Population-based studies of varicella complications. *Pediatrics*. 1986 Oct;78(4):723-7.
3. Prakash J, Rathore SS, Choudhury TA, Singh TB. Chicken pox in adult renal transplant patients: A report of two cases with review of literature. *Indian Journal of Transplantation*. 2012 Jan 1;6(1):27-9.
4. Cukuranovic J, Ugrenovic S, Jovanovic I, Visnjic M, Stefanovic V. Viral infection in renal transplant recipients. *The Scientific World Journal*. 2012 Jan 1;2012.
5. Rommelaere M, Maréchal C, Yombi JC, Goffin E, Kanaan N. Disseminated varicella zoster virus infection in adult renal transplant recipients: outcome and risk factors. In *Transplantation proceedings* 2012 Nov 1 (Vol. 44, No. 9, pp. 2814-2817). Elsevier.
6. Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, Gallon L, Garvey CA, Guleria S, Li PK, Segev DL. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. *Transplantation*. 2017 Aug;101(8 Suppl 1):S7.
7. Marcén R. Immunosuppressive Drugs in Kidney Transplantation. *Drugs*. 2009;69(16):2227-2243.
8. Renoult E, Lanthier S, Rouleau D, Jodoin N, Letourneau-Guillon L, Pâquet M, St-Louis G, Duclos A, St-Jean L, Léveillé M, Fortin MC. Varicella zoster virus vasculopathy after kidney transplantation. *Transplantation*. 2016 Apr 1;100(4):e19-20.
9. Rudiansyah M, Lubis L, Ria B, Sanjaya BM, Martakusumah AH, Achmad H, Roesli RM, Rachmadi D. The Correlation between Fibroblast Growth Factor 23 (FGF23) and Iron Profile in Chronic Kidney Disease Patients on Dialysis with Anemia. *Systematic Reviews in Pharmacy*. 2020;11(6):780-4.
10. Os I, Ström EH, Stenehjem A, Gudmundsdottir H, Langberg H, Draganov B, Godøy J, Dunlop O, von der Lippe B. Varicella infection in a renal transplant recipient associated with abdominal pain, hepatitis, and glomerulonephritis. *Scandinavian journal of urology and nephrology*. 2001 Jan 1;35(4):330-3.
11. Arness T, Pedersen R, Dierkhising R, Kremers W, Patel R. Varicella zoster virus-associated disease in adult kidney transplant recipients: incidence and risk-factor analysis. *Transplant Infectious Disease*. 2008 Aug;10(4):260-8.
12. Pergam SA, Limaye AP. Varicella zoster virus in solid organ transplantation. *Am J Transplant*. 2013;13(SUPPL.4):138-143.
13. Kaul A, Sharma RK, Bhadhuria D, Gupta A, Prasad N. Chickenpox infection after renal transplantation. *Clinical kidney journal*. 2012 Jun 1;5(3):203-6.

